Ironwood Announces the Completion of Squeeze-Out Merger With VectivBio
BASEL, Switzerland, June 26, 2023 (GLOBE NEWSWIRE) -- VectivBio Holding AG (œVectivBio) (Nasdaq: VECT), a global clinical-stage biopharmaceutical company pioneering novel, transformational...
BOSTON & BASEL, Switzerland--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (“Ironwood”) (Nasdaq: IRWD), a GI-focused healthcare company, and VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a global clinical-stage biopharmaceutical company pioneering novel, transformational treatments for severe rare gastrointestinal conditions, today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (“HSR”), in connection with Ironwood’s pending acquisition of VectivBio, expired at 11:59 p.m., Eastern Time, on June 15, 2023.
Having tasted blockbuster success with its irritable bowel syndrome (IBS) drug Linzess, Ironwood Pharmaceuticals is willing to pay $1 billion for the chance to make lightning strike twice.
Ironwood Enters into Definitive Agreement to Acquire VectivBio, a Clinical-Stage Biotech nCompany Pioneering Novel Treatments for Severe Rare Gastrointestinal Diseases
BASEL, Switzerland, May 10, 2023 (GLOBE NEWSWIRE) -- VectivBio Holding AG (âœVectivBioâ) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for...
VectivBio Reports Full Year 2022 Financial Results and Provides Business Update
VectivBio to Report Full Year 2022 Financial Results and Provide Business Update on Wednesday, April 19, 2023
VectivBio and Asahi Kasei Pharma Announce the Start of a Phase 1Â Study of Apraglutide in Japan
VectivBio Announces Results of Extraordinary General Meeting